title: Penetration of moxifloxacin into rat mandibular bone and soft tissue.
abstract: OBJECTIVE
  Based on its in vitro activity and spectrum of activity, the new 8-methoxyquinolone antibiotic moxifloxacin (MXF) seems suited for the antibiotic therapy of odontogenic infections. Penetration into the relevant tissue is another prerequisite for clinical efficacy. For this reason, the levels of MXF in plasma, soft tissue, and mandibular bone were determined in an animal model with Wistar rats.
  
  
  METHODS
  Samples of 49 rats were analyzed. Tissue samples were homogenized and proteins were precipitated. The pharmacokinetic evaluation was conducted based on non-compartmental analysis.
  
  
  RESULTS
  The concentration-time courses of tissues show a more plateau-shaped curve compared to plasma. Calculated AUC (area under the curve) ratios tissue:plasma were M. masseter:plasma = 2.64 and mandibles:plasma = 1.13.
  
  
  CONCLUSIONS
  Administration of antibiotics is considered an important part of therapy during and/or after surgical procedures in the maxillofacial area. Because of the good penetration into bone and muscle tissues demonstrated in Wistar rats, MXF might be an option for clinical application in this indication.
authors.affiliation: Center of Oral and Dental Medicine, Department of Restorative and Preventive Dentistry, University of Hamburg, Hamburg, Germany. cachovan@uke.uni-hamburg.de
authors.forename: Georg
authors.initials: G
authors.lastname: Cachovan
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Nergiz
authors.forename: Uwe
authors.initials: U
authors.lastname: Thuss
authors.forename: Hans-Martin
authors.initials: HM
authors.lastname: Siefert
authors.forename: Ingo
authors.initials: I
authors.lastname: Sobottka
authors.forename: Okhan
authors.initials: O
authors.lastname: Oral
authors.forename: Ursula
authors.initials: U
authors.lastname: Platzer
authors.forename: Ozen
authors.initials: O
authors.lastname: Dogan-Onur
mesh_terms: D000539:Alveolar Process / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D000890:Anti-Infective Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001372:Aza Compounds / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D024841:Fluoroquinolones; D007239:Infections / Q000188:drug therapy; D008297:Male; D008334:Mandible / Q000187:drug effects / Q000378:metabolism; D008406:Masseter Muscle / Q000187:drug effects / Q000378:metabolism*; D000077266:Moxifloxacin; D010510:Periodontal Diseases / Q000188:drug therapy*; D011804:Quinolines / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014076:Tooth Diseases / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin